Affiliation:
1. Moscow Ophthalmology Clinic
Abstract
Introduction. Meibomian gland dysfunction (MGD) is considered as the leading cause of the evaporative dry eye syndrome (DES). At the same time the standard methods of DES treatment often allow to achieve only a short-term effect and the search of alternative methods to achieve remission for a longer period is required.Aim. To evaluate the effectiveness of a combined treatment of DES with MGD using transdermal Intense Pulsed Light (IPL) method combined with preservative-free sodium hyaluronate 0.18% eyedrops.Materials and methods. The study involved 60 patients (120 eyes) after refractive surgery (femtoLASIK) with DES and MGD aged 20 to 40 years with a follow-up period of 3 months. The patients were divided into two groups: main (30 patients) and control (30 patients). Patients of both groups were administered a preservative-free form of 0.18% sodium hyaluronate four times a day for 3 months. All studied patients underwent standard examination methods, indicators of DES were assessed along with an objective valuation of tear film parameters and the meibomian glands condition by mean of digital biomicroscopy using a MediWorks slit lamp before surgery and 7 days, 1, 2 and 3 months after refractive surgery.Results and discussion. A comparative analysis of therapy effectiveness in the main and control groups showed that OSDI scores (ocular surface disease index), non-invasive tear breakup time (NITBUT) and meibomian gland function improved after treatment in both groups, but in the main group (IPL) positive dynamics of indicators were more pronounced with a cumulative increase of effectiveness after subsequent sessions.Conclusion. A course of IPL therapy in combination with a course of sodium hyaluronate 0.18% for dry eye syndrome due to MGD reduces the time, allows for longer-term results of therapy and promotes earlier elimination of discomfort.
Reference69 articles.
1. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. https://doi.org/10.1016/j.jtos.2017.05.008.
2. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334–365. https://doi.org/10.1016/j.jtos.2017.05.003.
3. Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;(3):405–412. https://doi.org/10.2147/OPTH.S5555.
4. Бржеский ВВ, Егорова ГБ, Егоров ЕА. Синдром «сухого глаза» и заболевания глазной поверхности: клиника, диагностика, лечение. М.: ГЭОТАРМедиа., 2016. 464 c. Режим доступа: https://www.fkbook.ru/prod_show.php?object_uid=2209162.
5. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922–1929. https://doi.org/10.1167/iovs.10-6997a.